JP2013501075A - タンパク質精製におけるウイルス除去の改良方法 - Google Patents

タンパク質精製におけるウイルス除去の改良方法 Download PDF

Info

Publication number
JP2013501075A
JP2013501075A JP2012523983A JP2012523983A JP2013501075A JP 2013501075 A JP2013501075 A JP 2013501075A JP 2012523983 A JP2012523983 A JP 2012523983A JP 2012523983 A JP2012523983 A JP 2012523983A JP 2013501075 A JP2013501075 A JP 2013501075A
Authority
JP
Japan
Prior art keywords
antibody
protein
antibodies
virus
filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012523983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501075A5 (enExample
Inventor
アミト メータ，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013501075(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2013501075A publication Critical patent/JP2013501075A/ja
Publication of JP2013501075A5 publication Critical patent/JP2013501075A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012523983A 2009-08-06 2010-08-06 タンパク質精製におけるウイルス除去の改良方法 Withdrawn JP2013501075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23181109P 2009-08-06 2009-08-06
US61/231,811 2009-08-06
PCT/US2010/044760 WO2011031397A1 (en) 2009-08-06 2010-08-06 Method to improve virus removal in protein purification

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015252787A Division JP2016106096A (ja) 2009-08-06 2015-12-25 タンパク質精製におけるウイルス除去の改良方法
JP2017121588A Division JP2017206529A (ja) 2009-08-06 2017-06-21 タンパク質精製におけるウイルス除去の改良方法

Publications (2)

Publication Number Publication Date
JP2013501075A true JP2013501075A (ja) 2013-01-10
JP2013501075A5 JP2013501075A5 (enExample) 2015-04-09

Family

ID=42985499

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012523983A Withdrawn JP2013501075A (ja) 2009-08-06 2010-08-06 タンパク質精製におけるウイルス除去の改良方法
JP2015252787A Pending JP2016106096A (ja) 2009-08-06 2015-12-25 タンパク質精製におけるウイルス除去の改良方法
JP2017121588A Pending JP2017206529A (ja) 2009-08-06 2017-06-21 タンパク質精製におけるウイルス除去の改良方法
JP2019163497A Withdrawn JP2020023491A (ja) 2009-08-06 2019-09-09 タンパク質精製におけるウイルス除去の改良方法
JP2022185354A Withdrawn JP2023029853A (ja) 2009-08-06 2022-11-21 タンパク質精製におけるウイルス除去の改良方法
JP2024159627A Pending JP2025003999A (ja) 2009-08-06 2024-09-13 タンパク質精製におけるウイルス除去の改良方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015252787A Pending JP2016106096A (ja) 2009-08-06 2015-12-25 タンパク質精製におけるウイルス除去の改良方法
JP2017121588A Pending JP2017206529A (ja) 2009-08-06 2017-06-21 タンパク質精製におけるウイルス除去の改良方法
JP2019163497A Withdrawn JP2020023491A (ja) 2009-08-06 2019-09-09 タンパク質精製におけるウイルス除去の改良方法
JP2022185354A Withdrawn JP2023029853A (ja) 2009-08-06 2022-11-21 タンパク質精製におけるウイルス除去の改良方法
JP2024159627A Pending JP2025003999A (ja) 2009-08-06 2024-09-13 タンパク質精製におけるウイルス除去の改良方法

Country Status (25)

Country Link
US (5) US10662237B2 (enExample)
EP (3) EP4559926A3 (enExample)
JP (6) JP2013501075A (enExample)
KR (3) KR20180035936A (enExample)
CN (2) CN102712691A (enExample)
AU (1) AU2010292897B2 (enExample)
BR (1) BR112012002574A2 (enExample)
CA (1) CA2770235C (enExample)
DK (1) DK2462158T3 (enExample)
ES (1) ES2662529T3 (enExample)
HR (1) HRP20180309T1 (enExample)
HU (1) HUE038451T2 (enExample)
IL (3) IL217740B (enExample)
LT (1) LT2462158T (enExample)
MX (1) MX346115B (enExample)
MY (1) MY188566A (enExample)
NO (1) NO2462158T3 (enExample)
NZ (1) NZ597809A (enExample)
PL (1) PL2462158T3 (enExample)
PT (1) PT2462158T (enExample)
RU (1) RU2573894C2 (enExample)
SG (1) SG178276A1 (enExample)
SI (1) SI2462158T1 (enExample)
WO (1) WO2011031397A1 (enExample)
ZA (1) ZA201200626B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504366A (ja) * 2014-10-21 2018-02-15 ジェンノヴァ バイオファーマシューティカルズ リミテッド 組換えｔｎｋ−ｔｐａ（テネクテプラーゼ）の単離及び商業生産のための新規精製方法
JP2018510166A (ja) * 2015-03-23 2018-04-12 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ウイルス濾過
JP2022523025A (ja) * 2019-01-28 2022-04-21 アムジエン・インコーポレーテツド 原薬及び製剤プロセスの統合による生物製剤製造のための連続的な製造プロセス

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527425A1 (en) 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
NO2462158T3 (enExample) 2009-08-06 2018-06-09
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CA2830640A1 (en) * 2011-03-25 2012-10-04 Genentech, Inc. Novel protein purification methods
DE102011105525B4 (de) 2011-06-24 2015-03-26 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Biopolymer-Aggregaten und Viren aus einem Fluid
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
HRP20181846T1 (hr) 2011-12-22 2018-12-28 Genentech, Inc. Kromatografija membranom za ionsku izmjenu
KR102260855B1 (ko) 2013-09-13 2021-06-04 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
NZ756749A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
EP3639911B1 (en) * 2017-06-12 2024-07-31 Asahi Kasei Medical Co., Ltd. Filtration method for protein-containing liquid
KR102753090B1 (ko) * 2017-12-21 2025-01-14 젠자임 코포레이션 단백질 a 크로마토그래피 동안 불순물의 향상된 제거를 위한 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108955A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
EP0397687B1 (en) 1987-12-21 1994-05-11 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH02198687A (ja) 1989-01-26 1990-08-07 Asahi Chem Ind Co Ltd 純水の製造方法
JPH038759A (ja) 1989-03-16 1991-01-16 Sumitomo Metal Ind Ltd 半導体磁器物質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
CN1130353A (zh) * 1993-07-09 1996-09-04 史密丝克莱恩比彻姆公司 蛋白质的纯化
HU218159B (hu) * 1993-09-21 2000-06-28 Hemosol Inc. Kiszorításos kromatográfiás eljárás tisztított hemoglobintermék előállítására
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
JP3415222B2 (ja) 1993-10-20 2003-06-09 東洋濾紙株式会社 エンドトキシン吸着能を有するポリエーテルサルホン又はスルホン化ポリエーテルサルホン微孔膜
JP3453623B2 (ja) 1994-03-30 2003-10-06 サンスター株式会社 エンドトキシン吸着除去剤および除去方法
DE69520042T2 (de) 1994-07-28 2001-07-19 Millipore Corp., Bedford Porösesverbundmembran und verfahren
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
ES2195112T5 (es) 1996-02-06 2015-10-15 Roche Diagnostics Gmbh Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo
TW505655B (en) 1997-10-14 2002-10-11 Tanox Inc Enhanced aggregate removal from bulk-biologicals using ion exchange chromatography
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
ES2267552T3 (es) 1999-07-30 2007-03-16 Genentech, Inc. Membranas de filtracion cargadas y sus usos.
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
AU2003272368C1 (en) 2002-09-13 2009-07-23 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
US20040116676A1 (en) 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
EP1403274A1 (en) 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
US20060257972A1 (en) 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
IN2009KN02655A (enExample) * 2003-12-10 2015-10-23 Medarex Inc
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
BRPI0507298A (pt) 2004-01-30 2007-07-03 Suomen Punainen Risti Veripalv processo para a produção de imunoglobulina segura a vìrus
US7390403B2 (en) 2004-03-19 2008-06-24 Millipore Corporation Prefilter system for biological systems
US7776821B2 (en) 2004-10-21 2010-08-17 Statens Serum Institut Method comprising nanofiltration to obtain an MBL product safe from infectious agents and the product obtainable by this method
EP1858928A2 (en) * 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2008025747A1 (en) 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US20080132688A1 (en) 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
SI2087002T1 (sl) 2006-10-27 2014-11-28 Lpath, Inc. Sestavki in postopki za vezavo sfingozin-1-fosfata
WO2008073620A2 (en) 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
SI2078071T1 (sl) 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
TWI601823B (zh) 2007-04-26 2017-10-11 中外製藥股份有限公司 Cell culture methods using media containing high concentrations of amino acids
AU2008343347A1 (en) 2007-12-21 2009-07-09 Genentech, Inc. Crystallization of anti-CD20 antibodies
EP2281000A2 (en) 2008-05-15 2011-02-09 Novo Nordisk A/S Antibody purification process
US9056896B2 (en) * 2009-03-27 2015-06-16 Asahi Kasei Medical Co., Ltd. Method for removing viruses from high concentration monoclonal antibody solution
SG176256A1 (en) 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
NO2462158T3 (enExample) 2009-08-06 2018-06-09
CN108409829A (zh) 2009-09-01 2018-08-17 弗·哈夫曼-拉罗切有限公司 通过改进的a蛋白洗脱增强的蛋白质纯化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108955A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
WO2009017491A1 (en) * 2006-06-14 2009-02-05 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014048665; Ｃｈｅｍ．　Ｅｎｇ．　Ｐｒｏｇ．　（２００８）　ｖｏｌ．１０４，　ｎｏ．５，　ｐ．Ｓ１４-Ｓ２０ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504366A (ja) * 2014-10-21 2018-02-15 ジェンノヴァ バイオファーマシューティカルズ リミテッド 組換えｔｎｋ−ｔｐａ（テネクテプラーゼ）の単離及び商業生産のための新規精製方法
JP7086601B2 (ja) 2014-10-21 2022-06-20 ジェンノヴァ バイオファーマシューティカルズ リミテッド 組換えｔｎｋ－ｔｐａ（テネクテプラーゼ）の単離及び商業生産のための新規精製方法
JP2018510166A (ja) * 2015-03-23 2018-04-12 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ウイルス濾過
JP2022058979A (ja) * 2015-03-23 2022-04-12 アレクシオン ファーマシューティカルズ インコーポレイテッド ウイルス濾過
JP7133925B2 (ja) 2015-03-23 2022-09-09 アレクシオン ファーマシューティカルズ インコーポレイテッド ウイルス濾過
US11919925B2 (en) 2015-03-23 2024-03-05 Alexion Pharmaceuticals, Inc. Virus filtration
JP7475381B2 (ja) 2015-03-23 2024-04-26 アレクシオン ファーマシューティカルズ インコーポレイテッド ウイルス濾過
JP2022523025A (ja) * 2019-01-28 2022-04-21 アムジエン・インコーポレーテツド 原薬及び製剤プロセスの統合による生物製剤製造のための連続的な製造プロセス
JP7617004B2 (ja) 2019-01-28 2025-01-17 アムジエン・インコーポレーテツド 原薬及び製剤プロセスの統合による生物製剤製造のための連続的な製造プロセス

Also Published As

Publication number Publication date
PL2462158T3 (pl) 2018-05-30
IL273486A (en) 2020-05-31
EP4559926A3 (en) 2025-08-06
JP2023029853A (ja) 2023-03-07
HUE038451T2 (hu) 2018-10-29
MX346115B (es) 2017-03-08
IL273486B (en) 2022-04-01
RU2012108318A (ru) 2013-09-20
US10662237B2 (en) 2020-05-26
LT2462158T (lt) 2018-03-26
AU2010292897B2 (en) 2016-01-07
EP2462158B1 (en) 2018-01-10
CN106905413A (zh) 2017-06-30
JP2025003999A (ja) 2025-01-14
KR20130051431A (ko) 2013-05-20
IL217740B (en) 2020-04-30
EP3309168A1 (en) 2018-04-18
ES2662529T3 (es) 2018-04-06
KR20190018041A (ko) 2019-02-20
IL287431A (en) 2021-12-01
EP4559926A2 (en) 2025-05-28
JP2017206529A (ja) 2017-11-24
CA2770235C (en) 2021-06-29
MX2012001659A (es) 2012-04-30
NO2462158T3 (enExample) 2018-06-09
IL217740A0 (en) 2012-03-29
US20220306726A1 (en) 2022-09-29
US20240083980A1 (en) 2024-03-14
PT2462158T (pt) 2018-02-23
EP2462158A1 (en) 2012-06-13
CA2770235A1 (en) 2011-03-17
MY188566A (en) 2021-12-22
WO2011031397A1 (en) 2011-03-17
NZ597809A (en) 2014-05-30
SG178276A1 (en) 2012-03-29
US11225513B2 (en) 2022-01-18
US20110034674A1 (en) 2011-02-10
KR101844859B1 (ko) 2018-05-18
SI2462158T1 (en) 2018-04-30
KR20180035936A (ko) 2018-04-06
JP2020023491A (ja) 2020-02-13
HRP20180309T1 (hr) 2018-03-23
ZA201200626B (en) 2013-06-26
DK2462158T3 (en) 2018-03-05
AU2010292897A1 (en) 2012-02-16
US20250282850A1 (en) 2025-09-11
JP2016106096A (ja) 2016-06-16
CN102712691A (zh) 2012-10-03
US20200347118A1 (en) 2020-11-05
RU2573894C2 (ru) 2016-01-27
BR112012002574A2 (pt) 2020-11-03

Similar Documents

Publication Publication Date Title
US20240083980A1 (en) Method to improve virus filtration capacity
KR100960211B1 (ko) 이온 교환 크로마토그래피에 의한 단백질 정제 방법
RU2594163C2 (ru) Способы очистки полипептидов
JP2021138769A (ja) タンパク質精製
TW201840580A (zh) 純化抗體的方法
JP2001510483A (ja) タンパク質の回収
CN102573459A (zh) 粘度降低的浓缩多肽制剂
HK1239715A1 (en) Method to improve virus removal in protein purification
HK1174339A (en) Method to improve virus removal in protein purification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141118

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160107

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170522

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170719